Indolent B-Cell Lymphoma
Indolent B-Cell Lymphoma
The latest news, research, and perspectives in indolent B-cell lymphoma. This diverse group of slow-growing non-Hodgkin lymphomas form in B cells and include follicular lymphoma, hairy cell leukemia, and marginal zone lymphoma.
Advertisement
Blood Cancers Today Staff WritersVideo Insights | January 17, 2023
The panel discusses new targets for DLBCL and FL and shares what excites them about the future for these diseases.
View More
Blood Cancers Today Staff WritersVideo Insights | January 13, 2023
The panel discusses regulatory hurdles and patient access considerations for non-Hodgkin lymphoma therapies.
Blood Cancers Today Staff WritersVideo Insights | January 12, 2023
The panel discusses treatment sequencing after CAR-T or transplant and the role bispecifics and other regimens may play.
Blood Cancers Today Staff WritersVideo Insights | January 12, 2023
The panel discusses combination therapy options for patients with DLBCL and FL.
Blood Cancers Today Staff WritersVideo Insights | January 9, 2023
The panel discusses novel treatment options for FL, including bispecifics, CAR-Ts, monoclonal antibodies, and more.
Blood Cancers Today Staff WritersVideo Insights | January 9, 2023
The panel talks about novel therapies for DLBCL, including the timing and sequencing for such treatments and more.
Advertisement
Blood Cancers Today Staff WritersVideo Insights | December 21, 2022
The panel discusses barriers to improving treatment options for patients with DLBCL and follicular lymphoma.
Blood Cancers Today Staff WritersVideo Insights | December 21, 2022
A panel discusses the unmet needs and emerging therapeutic areas for DLBCL and follicular lymphoma.
Leah SherwoodMyeloma | December 1, 2022
At Blood Cancers Today, we have compiled the year's top content awards as doled out by the Twitterverse. 
Leah SherwoodPrint | November 23, 2022
Manali Kamdar, MD; and Craig S. Sauter, MD, FACP; debate CAR T-cell therapy and AHSCT in second-line DLBCL.
Cecilia BrownIndolent B-Cell Lymphoma | November 15, 2022
Patients with LBCL received prophylactic anakinra to reduce the risk of cytokine release syndrome following CAR-T.
Leah SherwoodIndolent B-Cell Lymphoma | October 12, 2022
Orelabrutinib monotherapy may be an option for relapsed/refractory Waldenström’s macroglobulinemia.
Leah LawrenceIndolent B-Cell Lymphoma | June 23, 2022
Eighty percent of patients with marginal zone lymphoma (MZL) experienced tumor response with zanubrutinib monotherapy, ...
Leah LawrenceIndolent B-Cell Lymphoma | June 8, 2022
Umbralisib was approved to treat marginal zone lymphoma (MZL) and follicular lymphoma (FL).
Leah LawrenceIndolent B-Cell Lymphoma | June 8, 2022
The U.S. Food and Drug Administration (FDA) has granted tisagenlecleucel accelerated approval for adult patients with ...
Leah LawrenceIndolent B-Cell Lymphoma | May 31, 2022
The regimen improved overall survival in patients with MYC-translocated lymphomas.
Leah LawrenceTransplantation & Cellular Therapy | March 2, 2022
Clinicians are excited to see how many patients could benefit with CAR T-cell therapy.
Ariel DeMaioAggressive B-Cell Lymphoma | March 2, 2022
Pivotal trials that supported FDA approval of CAR T-cell therapies had low proportions of Black patients enrolled.
Sabrina AhleIndolent B-Cell Lymphoma | March 2, 2022
Allogene Therapeutics has been cleared by the U.S. Food and Drug Administration (FDA) to resume trials of its allogeneic ...
Sabrina AhleIndolent B-Cell Lymphoma | March 2, 2022
After failing to complete the requisite confirmatory trials following accelerated approval, Gilead has announced it will ...
Advertisement
Advertisement
Editorial Board